Could Artiva’s NK cells drive cell therapy-like activity with biologics-like ease of use?
- Highlight the rationale and potential advantages of utilizing a non-genetically modified NK cell therapy in combination with monoclonal antibodies in autoimmune diseases
- Explore clinical data demonstrating that NK cell therapies can drive deep B-cell depletion in autoimmune disease while avoiding side effects inherent in CAR-T and TCE therapies
- Highlight a framework for selecting indications for different cell therapies based on their potential target product profile